Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT1 Safety and PK in Healthy Adults
NCT06610487Phase 1Completed
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of notoginsenoside Ft1 in diarrhea (4 arms), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd. Primary endpoint: Treatment-related Adverse Events at 43 days. Started Aug 2024; status: completed.
02
Drugs
notoginsenoside Ft1
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT06610487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610487.